Introduction to Liraglutide and Semaglutide Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has important effects on glycemic control as it stimulates insulin secretion and inhibits glucagon release, making it the perfect candidate for a therapeutically effective anti-diabetic agent
The article says combination therapy is typically considered when glycemic control is inadequate on GLP-1 monotherapy, or when cost, adherence or side effects favor adding an oral DPP-4 instead of increasing the GLP-1 amount
45, Northside Plaza, Suite 107, Pomona, NY | (845) 362-1300 | [email protected] | www.nicrd.com This article is for educational purposes only and does not constitute individual medical advice.
Afamelanotide (Scenesse, Clinuvel Pharmaceuticals) is a linear MC1R selective tridecapeptide, approved by the FDA on October 8, 2019, and by the EMA on December 22, 2014, exclusively for the treatment of erythropoietic protoporphyria (EPP) in adults
But there is very little data on how the drug works in humans
Interestingly, we found that fat-7(-) mutants exhibited partial resistance to MID (Fig